Chondroprotective effects of a proanthocyanidin rich Amazonian genonutrient reflects direct inhibition of matrix metalloproteinases and upregulation of IGF-1 production by human chondrocytes.
BACKGROUND
The Amazonian medicinal plant Sangre de grado (Croton palanostigma) has traditional applications for the treatment of wound healing and inflammation. We sought to characterize two extracts (progrado and zangrado) in terms of safety and oligomeric proanthocyanidin chain length. Additionally progrado was evaluated for antioxidant activity and possible chondroprotective actions.


METHODS
Acute oral safety and toxicity was tested in rats according under OECD protocol number 420. The profile of proanthocyanidin oligomers was determined by HPLC and progrado's antioxidant activity quantified by the ORAC, NORAC and HORAC assays. Human cartilage explants, obtained from surgical specimens, were used to assess chondroproteciton with activity related to direct inhibitory effects on human matrix metalloproteinase (MMP, gelatinolytic) activity using synovial fluid and chondrocytes activated with IL-1beta (10 ng/ml). Additionally, progrado (2-10 mug/ml) was tested for its ability to maintain optimal IGF-1 transcription and translation in cartilage explants and cultured chondrocytes.


RESULTS
Both progrado and zangrado at doses up to 2000 mg/kg (po) displayed no evidence of toxicity. Oligomeric proanthocyanidin content was high for both progrado (158 mg/kg) and zangrado (124 mg/kg), with zangrado almost entirely composed of short oligomers (<6 mer), whereas the majority of oligomers in progrado exceeded 10 mers. Progrado was a remarkably potent antioxidant in the standardized tests ORAC, NORAC and HORAC. Progrado was exceptionally effective in reducing both basal and IL-1beta induced glycosaminoglycan release from human cartilage explants at concentrations that also directly blocked the gelatinolytic activity of MMP-2 and MMP-9. Progrado prevented IL-1beta induced suppression of IGF-1 production from human cartilage explants as well as stimulating basal IGF-1 production (P < 0.05). Comparable changes in IGF-1 gene expression were noted in cultured human chondrocytes.


CONCLUSIONS
Progrado has a promising safety profile, significant chondroprotective and antioxidant actions, directly inhibits MMP activity and promotes the production of the cartilage repair factor, IGF-1. This suggests that progrado may offer therapeutic benefits in joint health, wound healing and inflammation.
Miller
Mark Js
MJ
Center for Cardiovascular Sciences, Albany Medical College, Albany, New York, USA. markjsm03@yahoo.com.
Bobrowski
Paul
P
Shukla
Meenakshi
M
Gupta
Kalpana
K
Haqqi
Tariq M
TM
J Ethnopharmacol. 2002 May;80(2-3):121-9
12007701
BMC Complement Altern Med. 2006;6:13
16603065
J Invest Dermatol. 2001 Sep;117(3):725-30
11564183
Am J Physiol. 1999 Jan;276(1 Pt 1):G58-63
9886979
N Engl J Med. 2006 Feb 23;354(8):795-808
16495392
Free Radic Biol Med. 2002 Oct 15;33(8):1097-105
12374621
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4524-9
10200295
Ann Rheum Dis. 2001 Mar;60(3):254-61
11171688
J Orthop Res. 2005 Jan;23(1):118-26
15607883
J Nutr. 2005 Sep;135(9):2096-102
16140882
Am J Physiol. 1999 Apr;276(4 Pt 1):G795-9
10198320
Evid Based Complement Alternat Med. 2005 Sep;2(3):301-8
16136208
Gene Ther. 2005 Aug;12(15):1171-9
15815701
Phytochemistry. 1995 Apr;38(6):1319-43
7786474
Am J Physiol Gastrointest Liver Physiol. 2000 Jul;279(1):G192-200
10898763
Handb Exp Pharmacol. 2007;(179):155-71
17217056
J Orthop Res. 2003 Jan;21(1):102-9
12507586
Histochem J. 1996 Dec;28(12):835-57
9015706
Eur J Nutr. 2006 Dec;45(8):428-38
17036262
Arthritis Res Ther. 2004;6(5):R393-403
15380039
Planta Med. 1989 Apr;55(2):140-3
2748730
Pharmacol Rep. 2005;57 Suppl:97-107
16415490
Phytomedicine. 1994 Sep;1(2):77-106
23195881
Nature. 2006 Nov 16;444(7117):337-42
17086191
Am J Gastroenterol. 1999 Nov;94(11):3267-73
10566728
J Biol Chem. 2001 Oct 5;276(40):37258-65
11486009
Biochim Biophys Acta. 1986 Sep 4;883(2):173-7
3091074